Director Rupert Vessey of BIO-TECHNE Corp filed a Form 4 on November 2, 2026, reporting the acquisition of 2,750 shares of common stock on October 29, 2026, along with a new stock option grant.

Key Highlights

  • Share acquisition: Rupert Vessey acquired 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, at a price of $0.
  • Resulting ownership: Following the transaction, Vessey directly holds 13,737 shares of common stock, according to the filing.
  • New stock option: A stock option (right to buy) covering 3,777 shares of common stock was reported, with an exercise price of $60.96, exercisable October 29, 2026, and expiring October 30, 2035.
  • Total options held: The filing lists eight stock option grants directly held by Vessey, covering a combined 34,641 shares of common stock.
  • Reporting person's role: Vessey is identified as a Director of BIO-TECHNE Corp (NASDAQ:TECH).
  • Filing signed by: The form was signed by Andrew Nick as Attorney-in-Fact for Rupert Vessey pursuant to a previously filed power of attorney.

BIO-TECHNE Director Vessey's October 2026 Equity Transactions

According to the Form 4 filed with the SEC on November 2, 2026, Rupert Vessey, a director of BIO-TECHNE Corp (NASDAQ:TECH), reported the acquisition of 2,750 shares of the company's common stock on October 29, 2026. The transaction code was listed as "A" (acquisition), and the price recorded was $0, indicating no cash consideration paid. Following this transaction, Vessey's direct beneficial ownership of common stock stands at 13,737 shares, as disclosed in the filing.

In addition to the common stock acquisition, the filing discloses a new stock option grant. The option covers 3,777 shares of common stock at an exercise price of $60.96 per share, became exercisable on October 29, 2026, and expires on October 30, 2035. This option is held directly by Vessey. The filing also lists seven previously reported stock option grants, with exercise prices ranging from $50.41 to $128.81 per share and expiration dates ranging from June 30, 2029 to October 24, 2034, covering a total of 30,864 shares across those seven grants.

All reported stock options are classified as direct ownership. The form was filed by Andrew Nick as Attorney-in-Fact for Rupert Vessey under a power of attorney previously filed with the SEC. No amendment date was indicated, suggesting this is an original filing.

What Was Disclosed

The filing reports Director Rupert Vessey's acquisition of 2,750 BIO-TECHNE common shares at $0 on October 29, 2026, bringing his direct holdings to 13,737 shares, plus a new stock option for 3,777 shares at $60.96 expiring October 30, 2035.